On May 27, 2022, TYK Medicines, Inc. announced a partnership with Syneos Health to conduct a Phase I clinical trial of TY-2136b in the United States.

TY-2136b is a new-generation ROS1/NTRK/ALK multi-target inhibitor against drug resistance independently developed by TYK Medicines. It was submitted to the United States Food and Drug Administration (FDA) for IND application on October 19, 2021, and the official letter of approval from the FDA to conduct clinical trials was received on November 19, 2021.

The Syneos Health team said, “we will actively promote the TY-2136b project of TYK Medicine, and give full play to the professional level of our team to develop a series of solutions on protocol design, patients recruitment, risk control, so as to help complete the research objectives as soon as possible and provide better treatment for patients.”

“With the help of Syneos Health’s professional team, we hope to accelerate the clinical progress of TY-2136b in the United States, promote the pace of domestic medicine to the market, and benefit more patients as soon as possible,” TYK teams said.

About TY-2136b

TY-2136b is a new generation ROS1/NTRK/ALK multi-target small broad-spectrum tyrosine kinase inhibitor independently developed by TYK Medicines, Inc. TY-2136b is selective and highly potent against ROS1/TRKA-C/ALK/ and ALK/ROS1/NTRK-positive drug-resistant mutations and with CNS penetration, it potentially overcomes drug resistance triggered by acquired ROS1/NTRK/ALK mutations including G2032R, G595R, G667C, G623R, G1202R and double mutations, etc. TY-2136b is a potential therapy for advanced solid and metastatic tumors, especially for lung cancer and tumors with ALK/ROS1/NTRK alterations and ALK/ROS1/NTRK-positive drug-resistant mutations, effectively solving unmet clinical needs.

About TYK Medicines, Inc.

TYK Medicines is an innovative biotechnology company based in China, facing the global, focusing on researching and developing international cutting-edge new drugs. The company has established a high-efficiency innovative drug research and development platform, with fully functioned instruments, covering multiple pharmaceutical fields including drug synthesis, biological fermentation, drug analysis, bioanalysis, and formulation research, and is committed to becoming the best domestic and world-class new drug research and development company.